Our data would support the testing of an MDM2 inhibitor with either GO or InO in patients with TP53WT acute leukemia, whereas the combination of GO or InO with an ATM inhibitor could be explored in patients independent of the TP53 mutational status. The gene discussed is MDM2; the disease is acute leukemia.